Objectives

Section 1
Section 2
Section 3
Section 4
Section 5
Section 6
Section 7

> References

 
 

References

  1. Joint United Nations Programme on HIV/AIDS (UNAIDS). AIDS Epidemic Update, December 2004. Geneva, Switzerland: UNAIDS, 2004. [slide 4]

  2. UNAIDS, 2004. [slide 5]

  3. Central Bureau of Statistics (CBS), Kenya Ministry of Health (MOH), ORC Macro. 2004. Kenya Demographic and Health Survey 2003. Calverton, MD: CBS, MOH, and ORC Macro, July 2004. [slide 6]

  4. UNAIDS. Report on the Global HIV/AIDS Epidemic 2002. (Geneva, Switzerland: UNAIDS, 2002)128. [slide 7]

  5. Canadian International Development Agency (CIDA). HIV/AIDS in Africa. 2004. Available online. [slide 7]

  6. UNAIDS, 2004. [slide 8]

  7. UNAIDS, 2002. [slide 9]

  8. World Health Organization (WHO). Strategic Approaches to the Prevention of HIV Infection in Infants: Report of a WHO Meeting. Morges, Switzerland, March 20-22, 2002. Available online. [slide 12]

  9. U.S. Agency for International Development (USAID), Bureau for Global Health. Adding Family Planning to PMTCT Sites Increases the Benefits of PMTCT. Washington, DC: USAID, 2003. Available online. [slide 13]

  10. Population Reference Bureau. Datafinder. Indicator: Contraceptive Use Among Married Women, Modern Methods. Available online. [slide 15]

  11. Population Reference Bureau. Datafinder. Indicator: Unmet Need for Family Planning. Available online. [slide 15]

  12. Ross JA, Winfrey WL. Unmet need for contraception in the developing world and the former Soviet Union: an updated estimate. Int Fam Plann Perspect 2002;28(3):138-43. [slide 16]

  13. Saada M, Le Chenadec J, Berrebi A, et al. Pregnancy and progression to AIDS: results of the French prospective cohorts. SEROGEST and SEROCO Study Groups. AIDS 2000;14(15):2355-60. [slide 18]

  14. Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. BJOG 1998;105(8):836-48. [slide 18]

  15. Preble EA, Huber D, Piwoz EG. Family Planning and the Prevention of Mother-to-Child Transmission of HIV: Technical and Programmatic Issues. Arlington, VA: Advance Africa, 2003. [slide 19]

  16. Chen JL, Philips KA, Kanouse DE, et al. Fertility desires and intentions of HIV-positive men and women. Fam Plann Perspect 2001;33(4):144-52. [slide 21]

  17. King R, Estey J, Allen S, et al. A family planning intervention to reduce vertical transmission of HIV in Rwanda. AIDS 1995;9(Suppl. 1):S45-S51. [slide 22]

  18. WHO. Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach, 2003 Revision. Geneva, Switzerland: WHO, 2004a. [slide 26]

  19. Dabis F, Leroy V, Castetbon K, et al. Preventing mother-to-child transmission of HIV-1 in Africa in the year 2000. AIDS 2000;14(8):1017-26. [slide 27]

  20. Shelton JD, Peterson EA. The imperative for family planning in ART therapy in Africa. Lancet 2004;364(9449):1916-18. [slide 28]

  21. Powderly WG. Long-term exposure to lifelong therapies. J Acquir Immune Defic Syndr 2002;29(Suppl 1):S28-S40. [slide 28]

  22. WHO, 2004a. [slide 28]

  23. Cates W. Use of contraception by HIV-infected women. IPPF Med Bull 2001:35(1):1-2. [slide 30]

  24. Pariani S, Heer DM, Van Arsdol MD Jr. Does choice make a difference to contraceptive use? Evidence from East Java. Stud Fam Plann 1991;22(6):384-90. [slide 31]

  25. Huezo C, Malhotra U. Choice and Use-Continuation of Methods of Contraception: A Multicentre Study. London, UK: International Planned Parenthood Federation, 1993. [slide 31]

  26. WHO. Medical Eligibility Criteria for Contraceptive Use, Third Edition. Geneva, Switzerland: WHO, 2004b. [slide 40]

  27. WHO, 2004b. [slide 41]

  28. WHO, 2004b. [slide 42]

  29. WHO, 2004b. [slide 43]

  30. Hatcher RA, Trussell J, Stewart FH, et al. Contraceptive Technology, Eighteenth Revised Edition. New York: Ardent Media, Inc., 2004. [slide 45]

  31. Hatcher, 2004. [slide 46]

  32. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002;(1):CD003255. [slide 47]

  33. Deschamps M-M, Pape JW, Hafner A, et al. Heterosexual transmission of HIV in Haiti. Ann Inter Med 1996;125:324-30. [slide 47]

  34. Hatcher, 2004. [slide 47]

  35. WHO, 2004b. [slide 48]

  36. Diaz T, Schable B, Chu SY. Relationship between use of condoms and other forms of contraception among human immunodeficiency virus-infected women. Obstet Gynecol 1995;86(2):277-82. [slide 50]

  37. Leitz G, Mildvan D, McDonough M, et al. Nevirapine (VIRAMUNE, NCP) and ethinyl estradiol/norethindrone (ORTHO-NOVUM 1/35 [21 pack] EE/NET) interaction study in HIV-1 infected women. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, January 30-February 2, 2000. [slide 54]

  38. Piscitelli S, Flexner C, Minor J, et al. Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996;23(4):685-93. [slide 54]

  39. WHO, 2004b. [slide 56, slide 57]

  40. Mildvan D, Yarrish R, Marshak A, et al. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. J Acquir Immune Defic Syndr 2002;29(5):471-77. [slide 56]

  41. Ouellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 1998;46(2):111-116. [slide 57]

  42. GlaxoSmithKline. Agenerase® (amprenavir). Prescribing information. Research Triangle Park, NC: GlaxoSmithKline, 2004. Available online. [slide 57]

  43. Lavreys L, Chohan V, Overbaugh J, et al, Hormonal contraception and risk of cervical infections among HIV-1 seropositive Kenyan women. AIDS 2004;18(16):2179-84. [slide 59]

  44. Wang CC, Kreiss JK, Reilly M. Risk of HIV infection in oral contraceptive pill users: a meta-analysis. J Acquir Immune Defic Syndr 1999;21(1):51-58. [slide 60]

  45. Wang CC, McClelland RS, Overbaugh J, et al. The effect of hormonal contraception on genital tract shedding of HIV-1. AIDS 2004;18(2):205-9. [slide 60]

  46. John GC, Nduati RW, Mbori-Ngacha DA, et al. Correlates of mother-to-child human immuno-deficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 2001;183(2):206-12. [slide 60]

  47. McClelland RS, Wang CC, Mandaliya K, et al. Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS 2001;15(1):105-10. [slide 61]

  48. Ghys PD, Fransen K, Diallo MO, et al. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Cote d’Ivoire. AIDS 1997;(12):F85-93. [slide 61]

  49. Lavreys L, Baeten JM, Kreiss JK, et al. Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women. J Infect Dis 2004;189(2):303-11. [slide 62]

  50. Sagar M, Lavreys L, Baeten J, et al. Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J Virol 2003;77(23):12921-26. [slide 62]

  51. WHO, 2004b. [slide 63]

  52. Hatcher, 2004. [slide 64]

  53. WHO, 2004b. [slide 64]

  54. WHO, 2004b. [slide 65]

  55. Mildvan, 2002. [slide 65]

  56. Said S, Omar K, Koetsawang S, et al. A multicentred phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: 1. Contraceptive efficacy and side effects. World Health Organization Task Force on Long-Acting Systemic Agents for Fertility Regulation. Special Programme of Research, Development and Research Training in Human Reproduction.
    Contraception 1986;34(3):223-35. [slide 65]

  57. WHO, 2004b. [slide 66]

  58. Mildvan, 2002. [slide 66]

  59. Hatcher, 2004. [slide 68]

  60. Morrison CS, Sekadde-Kigondu C, Sinei SK, et al. Is the intrauterine device appropriate contraception for HIV-1-infected women? BJOG 2001;108(8):784-90. [slide 69]

  61. Richardson BA, Morrison CS, Sekadde-Kigondu C, et al. Effect of intrauterine device on cervical shedding of HIV-1 DNA. AIDS 1999;13(15):2091-97. [slide 70]

  62. WHO, 2004b. [slide 71]

  63. Hatcher, 2004. [slide 72]

  64. Wilkinson D, Ramjee G, Tholandi M, et al. Nonoxynol-9 for preventing vaginal acquisition of HIV infection by women from men (Cochrane Review). Cochrane Database Syst Rev 2002;(4):CD003936. [slide 72]

  65. Wilkinson D, Ramjee G, Tholandi M, et al. Nonoxynol-9 for preventing vaginal acquisition of sexually transmitted infections by women from men (Cochrane Review). Cochrane Database Syst Rev 2002;(4):CD003939. [slide 72]

  66. WHO, Contraceptive Research and Development Project (CONRAD). Safety of Nonoxynol-9 When Used for Contraception: Report from WHO/CONRAD Technical Consultation, October 2001. Geneva, Switzerland: WHO and CONRAD, 2002. Available online. [slide 72]

  67. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002;360(9338):971-77. [slide 72]

  68. Hatcher, 2004. [slide 73]

  69. Moench TR, Chipato T, Padian NS. Preventing disease by protecting the cervix: the unexplored promise of internal vaginal barrier devices. AIDS 2001;15(13):1595-1602. [slide 73]

  70. Hu J, Gardner MB, Miller CJ. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 2000;74(13):6087-95. [slide 73]

  71. WHO, 2004b. [slide 74]

  72. Gottlieb G, Nickle D, Jensen M, et al. HIV-1 superinfection in a rapid disease progressor: rapid replacement of the initial strain with the superinfecting virus by natural selection. Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 8-11, 2004. [slide 74]

  73. Hatcher, 2004. [slide 75]

  74. WHO, 2004b. [slide 76]

  75. Hatcher, 2004. [slide 77]

  76. WHO, 2004b. [slide 78]

  77. Nduati R, John G, Mbori-Ngacha D, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 2000;283(9):1167-74. [slide 78]

  78. De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 2000;283(9):1175-82. [slide 78]

  79. Hatcher, 2004. [slide 79]

  80. WHO, 2004b. [slide 80]

  81. Chervenak FA, McCullough LB. Common ethical dilemmas encountered in the management of HIV-infected women and newborns. Clin Obstet Gynecol 1996;39(2):411-19. [slide 84]

  82. McIntyre J. HIV in Pregnancy: A Review (Geneva, Switzerland: World Health Organization/UNAIDS, 1999)7. [slide 85]

  83. Bessinger R, Clark R, Kissinger P, et al. Pregnancy is not associated with the progression of HIV disease in women attending an HIV outpatient program. Am J Epidemiol 1998;147(5):434-40. [slide 85]

  84. Immunological markers in HIV-infected pregnant women. The European Collaborative Study and the Swiss HIV Pregnancy Cohort. AIDS 1997;11(15):1859-65. [slide 85]

  85. Vimercati A, Greco P, Lopalco PL, et al. Immunological markers in HIV-infected pregnant and non-pregnant women. Eur J Obstet Gynecol Reprod Biol 2000;90(1):37-41. [slide 85]

  86. Working Group on Mother-to-Infant Transmission of HIV. Rates of mother-to-infant transmission of HIV-1 in Africa, America, and Europe: results from 13 perinatal studies. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8(5):506-10. [slide 85]

  87. WHO Collaborative Study Team on the Role of Breastfeeding on the Prevention of Infant Mortality. Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed countries: a pooled analysis. Lancet 2000;355(9202):451-55. [slide 86]